2435 related articles for article (PubMed ID: 6540688)
1. Human monoclonal antibody to ganglioside GD2-inhibited human melanoma xenograft.
Katano M; Jien M; Irie RF
Eur J Cancer Clin Oncol; 1984 Aug; 20(8):1053-9. PubMed ID: 6540688
[TBL] [Abstract][Full Text] [Related]
2. Human monoclonal antibody to tumor-associated ganglioside GD2: suppressed growth of human melanoma in nude mice.
Katano M; Irie RF
Immunol Lett; 1984; 8(4):169-74. PubMed ID: 6542067
[TBL] [Abstract][Full Text] [Related]
3. Human monoclonal antibody to tumor-associated ganglioside GD2.
Katano M; Saxton RE; Irie RF
J Clin Lab Immunol; 1984 Nov; 15(3):119-26. PubMed ID: 6099419
[TBL] [Abstract][Full Text] [Related]
4. Human IgM monoclonal anti-GD2 antibody: reactivity to a human melanoma xenograft.
Katano M; Saxton RE; Tsuchida T; Irie RF
Jpn J Cancer Res; 1986 Jun; 77(6):584-94. PubMed ID: 3089993
[TBL] [Abstract][Full Text] [Related]
5. Radioimmunodetection of human melanoma tumor xenografts with human monoclonal antibodies.
Gomibuchi M; Saxton RE; Lake RR; Katano M; Irie RF
Int J Rad Appl Instrum B; 1986; 13(1):13-9. PubMed ID: 3771234
[TBL] [Abstract][Full Text] [Related]
6. Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2.
Cahan LD; Irie RF; Singh R; Cassidenti A; Paulson JC
Proc Natl Acad Sci U S A; 1982 Dec; 79(24):7629-33. PubMed ID: 6296843
[TBL] [Abstract][Full Text] [Related]
7. Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells.
Kawashima I; Yoshida Y; Taya C; Shitara H; Yonekawa H; Karasuyama H; Tada N; Furukawa K; Tai T
Int J Oncol; 2003 Aug; 23(2):381-8. PubMed ID: 12851687
[TBL] [Abstract][Full Text] [Related]
8. Cell surface reactive human monoclonal antibody directed to human melanoma-associated gangliosides.
Abdel-Wahab Z; Li WP; Darrow T; Nudelman ED; Towell A; Seigler HF
Melanoma Res; 1993 Dec; 3(6):415-23. PubMed ID: 8161881
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibody-defined correlations in melanoma between levels of GD2 and GD3 antigens and antibody-mediated cytotoxicity.
Thurin J; Thurin M; Kimoto Y; Herlyn M; Lubeck MD; Elder DE; Smereczynska M; Karlsson KA; Clark WM; Steplewski Z
Cancer Res; 1987 Mar; 47(5):1229-33. PubMed ID: 3815333
[TBL] [Abstract][Full Text] [Related]
10. Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis.
Cheresh DA; Honsik CJ; Staffileno LK; Jung G; Reisfeld RA
Proc Natl Acad Sci U S A; 1985 Aug; 82(15):5155-9. PubMed ID: 3860849
[TBL] [Abstract][Full Text] [Related]
11. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses.
Bolesta E; Kowalczyk A; Wierzbicki A; Rotkiewicz P; Bambach B; Tsao CY; Horwacik I; Kolinski A; Rokita H; Brecher M; Wang X; Ferrone S; Kozbor D
Cancer Res; 2005 Apr; 65(8):3410-8. PubMed ID: 15833876
[TBL] [Abstract][Full Text] [Related]
12. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.
Ragupathi G; Livingston PO; Hood C; Gathuru J; Krown SE; Chapman PB; Wolchok JD; Williams LJ; Oldfield RC; Hwu WJ
Clin Cancer Res; 2003 Nov; 9(14):5214-20. PubMed ID: 14614001
[TBL] [Abstract][Full Text] [Related]
13. Recombinant antibodies against ganglioside expressed on tumor cells.
Hanai N; Nakamura K; Shitara K
Cancer Chemother Pharmacol; 2000; 46 Suppl():S13-7. PubMed ID: 10950141
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects of a novel monoclonal antibody with high binding affinity to ganglioside GD3.
Ohta S; Honda A; Tokutake Y; Yoshida H; Hanai N
Cancer Immunol Immunother; 1993; 36(4):260-6. PubMed ID: 8439988
[TBL] [Abstract][Full Text] [Related]
15. Effect of anti-ganglioside antibodies on the metastatic spread of intraocular melanomas in a nude mouse model of human uveal melanoma.
Niederkorn JY; Mellon J; Pidherney M; Mayhew E; Anand R
Curr Eye Res; 1993 Apr; 12(4):347-58. PubMed ID: 8319494
[TBL] [Abstract][Full Text] [Related]
16. Immunorecognition of ganglioside epitopes: correlation between affinity and cytotoxicity of ganglioside antibodies.
Dippold W; Bernhard H
Eur J Cancer; 1992; 28A(10):1605-10. PubMed ID: 1382491
[TBL] [Abstract][Full Text] [Related]
17. Characterization of human IgG1 monoclonal antibody against gangliosides expressed on tumor cells.
Mukerjee S; Nasoff M; McKnight M; Glassy M
Hybridoma; 1998 Apr; 17(2):133-42. PubMed ID: 9627053
[TBL] [Abstract][Full Text] [Related]
18. Chimeric anti-ganglioside GM2 antibody with antitumor activity.
Nakamura K; Koike M; Shitara K; Kuwana Y; Kiuragi K; Igarashi S; Hasegawa M; Hanai N
Cancer Res; 1994 Mar; 54(6):1511-6. PubMed ID: 8137257
[TBL] [Abstract][Full Text] [Related]
19. Immune and nonimmune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialoganglioside GD3 on the surface of melanoma cells.
Welt S; Carswell EA; Vogel CW; Oettgen HF; Old LJ
Clin Immunol Immunopathol; 1987 Nov; 45(2):214-29. PubMed ID: 3665201
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibodies to disialogangliosides: characterization of antibody-mediated cytotoxicity against human melanoma and neuroblastoma cells in vitro.
Kawashima I; Tada N; Fujimori T; Tai T
J Biochem; 1990 Jul; 108(1):109-15. PubMed ID: 2121721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
